World's Best Scientists 2026 revealed!
Takuji Okusaka

Takuji Okusaka

D-Index & Metrics

Medicine

D-Index
96
Citations
43710
World Ranking
9525
National Ranking
261

Overview

Takuji Okusaka is affiliated with the National Cancer Centre in Japan. Their research primarily focuses on oncology within the medical field, with particular attention to pancreatic and hepatic oncology, cholangiocarcinoma and gallbladder cancer, as well as hepatocellular carcinoma treatment and prognosis.

The main fields of study covered in their work include:

  • Medicine

While the subfields of study where their research is concentrated consist of:

  • Oncology
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Hepatology
  • Epidemiology

The core topics addressed in Takuji Okusaka's publications are:

  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gallbladder and Bile Duct Disorders
  • Pediatric Hepatobiliary Diseases and Treatments
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Genomics and Diagnostics
  • Neuroendocrine Tumor Research Advances

Frequent collaborators include:

  • Masafumi Ikeda
  • Chigusa Morizane
  • Susumu Hijioka
  • Yoshikuni Nagashio
  • Junji Furuse

Okusaka has published extensively in various scientific venues, with a strong presence in the following journals:

  • Journal of Clinical Oncology
  • Endoscopy
  • Annals of Oncology
  • Japanese Journal of Clinical Oncology
  • Journal of Gastroenterology

Some of the recent papers contributing to the field include:

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, Journal of Clinical Oncology)
  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022, NEJM Evidence)
  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021, Journal of Clinical Oncology)
  • A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. (2022, Journal of Clinical Oncology)
  • Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition (2020, Journal of Hepato-Biliary-Pancreatic Sciences)

Best Publications

  • Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    James C. Yao;Manisha H. Shah;Tetsuhide Ito;Catherine Lombard Bohas

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Genomic spectra of biliary tract cancer

    Hiromi Nakamura;Yasuhito Arai;Yasushi Totoki;Tomoki Shirota

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

    Akihiro Fujimoto;Yasushi Totoki;Tetsuo Abe;Keith A. Boroevich

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

    Y Matsumura;T Hamaguchi;T Ura;K Muro

  • Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

    T Okusaka;K Nakachi;A Fukutomi;N Mizuno

  • Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

    Yasushi Totoki;Kenji Tatsuno;Kyle R. Covington;Hiroki Ueda

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer

    Akihiro Fujimoto;Mayuko Furuta;Yasushi Totoki;Tatsuhiko Tsunoda

  • Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

    Masatoshi Kudo;Kazuho Imanaka;Nobuyuki Chida;Kohei Nakachi

  • JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

    Masatoshi Kudo;Osamu Matsui;Namiki Izumi;Hiroko Iijima

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

    Yasuhito Arai;Yasushi Totoki;Fumie Hosoda;Tomoki Shirota

  • Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

    Hedy L Kindler;Tatsuya Ioka;Dirk J Richel;Jaafar Bennouna

  • Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis

    Tetsuhide Ito;Hisato Igarashi;Kazuhiko Nakamura;Hironobu Sasano

  • Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

    Juan W Valle;J Furuse;M Jitlal;S Beare

Frequent Co-Authors

Junji Furuse
Junji Furuse Kyorin University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Tomoo Kosuge
Tomoo Kosuge National Cancer Center
Andrew X. Zhu
Andrew X. Zhu Harvard University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Shoji Nakamori
Shoji Nakamori Osaka University
Hiromitsu Kumada
Hiromitsu Kumada Fukuoka University
Shuichi Kaneko
Shuichi Kaneko Kanazawa University
Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a future in Medicine but want flexible learning options, a range of related online degrees can help you start or advance your healthcare career. With rising demand for qualified healthcare professionals, taking courses online has become more accessible and respected by employers.

For those interested in entry-level nursing, online nursing programs offer affordable and flexible paths to get started as a registered nurse. If you are already a registered nurse seeking career advancement, rn to bsn online programs help you earn a bachelor’s degree, which can open doors to leadership and specialized roles.

Those from a non-nursing background can consider online direct entry msn options, fast-tracking your path to a master’s in nursing. For experienced nurses looking to move into research, teaching, or executive roles, a phd in nursing delivers advanced knowledge and skills.

Each of these online pathways helps build a strong foundation in healthcare, offering options to match different interests, education levels, and career goals within the medical field.

Best Scientists Citing Takuji Okusaka

Trending Scientists

Recently Published Articles